When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIMT - Aimmune up 9% premarket on successful AR101 study
Aimmune Therapeutics Inc.
Aimmune Therapeutics (NASDAQ:AIMT) is up 9% premarket on light volume in response to successful results from a European Phase 3 clinical trial, ARTEMIS, evaluating lead candidate AR101 for the treatment of peanut allergy.
More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the move,